Ketamine does not fit neatly into the “upper” or “downer” categories that people use to sort most recreational and pharmaceutical drugs. Pharmacologically, it is classified as a dissociative anesthetic, a label that reflects its signature effect: a sense of detachment from the body and surroundings driven primarily by blocking a specific type of receptor in the brain. What makes ketamine genuinely strange, and genuinely interesting, is that it produces effects borrowed from both stimulants and depressants while behaving like neither in any consistent way.
Why the Usual Categories Break Down
The “upper vs. downer” shorthand works reasonably well for many substances. Amphetamines speed up the central nervous system; benzodiazepines slow it down. Ketamine, however, does both at once, depending on which body system you look at. On the cardiovascular side, it acts like a stimulant: it raises blood pressure and heart rate. One study of patients receiving ketamine infusions for depression found that systolic blood pressure rose by an average of about 16 mmHg and diastolic by about 11 mmHg, peaking around 40 minutes after the infusion started. Roughly one in eight patients experienced a surge into the severe hypertension range.1PubMed. Blood pressure changes during ketamine infusion for the treatment of depression Acute intoxication can also produce agitation and tachycardia, effects you would normally associate with uppers.2Toxicology Reports. Rising incidence of recreational ketamine use: Clinical cases and management in emergency settings
Yet ketamine is also a powerful anesthetic. At higher doses it renders people unconscious. Even at lower doses it can produce dreamlike sedation, slurred speech, and impaired coordination, all hallmarks of downers. The key distinction is that unlike classical depressants such as opioids or barbiturates, ketamine at anesthetic doses preserves breathing and airway reflexes. Research comparing ketamine to propofol (a conventional sedative) found that ketamine actually stimulated the muscles that keep the airway open and maintained ventilation across a wide dose range.3PubMed Central. Ketamine Activates Breathing and Abolishes the Coupling between Loss of Consciousness and Upper Airway Dilator Muscle Dysfunction So even as ketamine is putting someone to sleep, it is simultaneously keeping their breathing muscles active in a way that alcohol or morphine would not.
This is why “dissociative” is not just a polite euphemism or a marketing label. It describes a genuinely distinct pharmacological profile in which consciousness is altered without the usual respiratory depression that defines classical downers, and without the hyperarousal that defines classical uppers.
How Ketamine Works in the Brain
The primary mechanism behind ketamine’s unusual effects is its blockade of NMDA receptors, which are gateways for the neurotransmitter glutamate, the brain’s main excitatory signal. By plugging these receptors, ketamine disrupts normal communication between brain regions, which is what produces the dissociative state: the feeling of being disconnected from your body, your environment, and sometimes your sense of self. Research has established that at plasma concentrations associated with clinical and recreational use, ketamine drives nearly all of its dissociative and psychotomimetic effects through this NMDA receptor blockade.4PubMed Central. Cortical Mechanisms Contributing to Ketamine-Induced Dissociation
But NMDA blockade is only the headline. Within clinical dose ranges, ketamine also acts on opioid receptors (both mu and delta subtypes), nicotinic acetylcholine receptors, and several other targets. It triggers increased release of dopamine and noradrenaline, which is part of why it has stimulant-like cardiovascular effects.5Trends in Anaesthesia and Critical Care. Ketamine – More mechanisms of action than just NMDA blockade A meta-analysis of ketamine’s dopaminergic effects found evidence that NMDA blockade on inhibitory interneurons leads to a chain reaction: those interneurons stop tamping down excitatory signals, which in turn increases firing of dopamine neurons, particularly in areas linked to reward and motivation.6Molecular Psychiatry. The effects of ketamine on dopaminergic function: meta-analysis and review of the implications for neuropsychiatric disorders That dopamine surge helps explain why some people experience euphoria on ketamine, and why the drug carries abuse potential.
The breadth of these targets is a big part of why ketamine resists simple classification. A drug that simultaneously blocks glutamate receptors, stimulates opioid receptors, boosts dopamine and noradrenaline, and alters acetylcholine signaling is playing multiple instruments at once, and the resulting “sound” is unlike any single drug category.
What the Dissociative Experience Actually Feels Like
People who have received ketamine, whether in a clinical setting or recreationally, describe a range of subjective states that do not map onto the expected trajectory of either a stimulant or a sedative. At low sub-anesthetic doses, users often report a floaty, detached sensation combined with mild euphoria and distorted perception of time. Music may sound different, the body may feel weightless or distant, and there is often a sense that the boundary between self and surroundings has blurred. At higher sub-anesthetic doses, complete dissociation can occur: the so-called “K-hole,” in which a person feels entirely separated from their physical body, sometimes experiencing vivid hallucinatory imagery.
An important finding from clinical research is that ketamine’s dissociative effects and its painkilling effects are actually independent of each other. A study that modeled both outcomes found that dissociation scores did not predict analgesia, and vice versa, meaning ketamine or its metabolites are activating distinct neural circuits for each effect.7PubMed Central. The dissociative and analgesic properties of ketamine are independent This matters because it tells us that dissociation is not just a side effect of painkilling, and painkilling is not just a consequence of being dissociated. Ketamine is doing several independent things at once, which is another reason a single category like “upper” or “downer” cannot capture what it does.
Ketamine’s Role as an Antidepressant
The biggest shift in how the medical world views ketamine over the past two decades has been the discovery that a single low dose can produce rapid antidepressant effects, sometimes within hours, in people with treatment-resistant depression. This is a dramatically faster timeline than conventional antidepressants, which typically take weeks to show benefit.
The mechanism appears to start with NMDA blockade on a specific type of brain cell: inhibitory interneurons that use the neurotransmitter GABA. When ketamine silences these interneurons, excitatory signaling in the prefrontal cortex surges, and glutamate release increases. Research has shown that knocking down a particular NMDA receptor subunit on GABA interneurons (including subtypes expressing somatostatin or parvalbumin) blocks ketamine’s antidepressant actions, while doing the same on excitatory neurons does not.8PubMed Central. GABA interneurons are the cellular trigger for ketamine’s rapid antidepressant actions In other words, the antidepressant effect depends on disinhibition: ketamine takes the brakes off certain circuits, and the resulting burst of activity triggers a cascade that ultimately leads to the growth of new synaptic connections.
That cascade involves the release of a growth factor called BDNF, which activates receptors that promote the insertion of new receptors on the receiving side of synapses, strengthening connections in brain areas like the prefrontal cortex and hippocampus.9Neuropsychopharmacology. Ketamine and rapid antidepressant action: new treatments and novel synaptic signaling mechanisms This synaptic remodeling is thought to underlie not just the rapid effect of ketamine but also the sustained improvement that can persist for days to weeks after a single dose. It is a fundamentally different antidepressant mechanism from the serotonin-boosting approach used by drugs like Prozac, and it is one reason ketamine is sometimes described as working through neuroplasticity. Classical psychedelics like psilocybin appear to promote similar structural changes in prefrontal cortex neurons, albeit through entirely different primary receptors.10PubMed. Neuroplasticity as a convergent mechanism of ketamine and classical psychedelics
What Ketamine Does to Brain Connectivity
Neuroimaging studies have begun to map how ketamine reshuffles communication across the brain. A randomized, placebo-controlled crossover study using simultaneous brain scanning found that after ketamine administration, connectivity in the medial prefrontal cortex decreased while connectivity in certain parietal regions increased.11PubMed Central. Ketamine effects on default mode network activity and vigilance: A randomized, placebo-controlled crossover simultaneous fMRI/EEG study The medial prefrontal cortex is a core hub of the default mode network, the brain system most active during self-referential thinking and mind-wandering. Disrupting that network may be part of why ketamine produces the characteristic sense of ego dissolution and detachment.
Some of these connectivity changes persist well after the drug itself has been cleared from the blood. One study found that decreased connectivity between two default mode network regions emerged not at one hour after infusion but at 24 hours, and that this delayed change correlated with shifts in glutamate levels in the prefrontal cortex.12PubMed. Default mode network connectivity change corresponds to ketamine’s delayed glutamatergic effects These lingering changes may be related to the sustained antidepressant effects described above, and they reinforce the idea that ketamine is not just temporarily altering brain chemistry the way a stimulant or sedative would. It is triggering changes that outlast its presence in the body.
Esketamine and Arketamine
The ketamine molecule comes in two mirror-image forms, called S-ketamine (esketamine) and R-ketamine (arketamine). The standard formulation used for decades is a 50/50 mix of both. But the two forms are not equally powerful. Esketamine delivers roughly three times stronger painkilling effects and about one and a half times greater anesthetic potency compared to arketamine, along with smoother sedation and fewer side effects.13PubMed Central. Ketamine, Esketamine, and Arketamine: Their Mechanisms of Action and Applications in the Treatment of Depression and Alleviation of Depressive Symptoms In 2019, the U.S. FDA approved esketamine as a nasal spray (brand name Spravato) specifically for treatment-resistant depression, making it the first ketamine-derived product with formal psychiatric approval.
Arketamine, the less potent mirror form, is now attracting research interest for potentially producing antidepressant effects with fewer dissociative side effects. Early evidence suggests arketamine might offer a more tolerable experience while still promoting the synaptic remodeling that underlies ketamine’s mood benefits, though this line of research is still in early clinical stages.
Medical Uses Beyond Psychiatry
Ketamine has been a mainstay of clinical medicine since the 1960s, valued precisely because it defies the upper-downer binary. For anesthesia, standard induction doses produce unconsciousness within about one to two minutes when given intravenously, and the drug’s short duration of action makes it easy to manage in operating rooms and field settings.14PubMed Central. Ketamine—50 years in use: from anesthesia to rapid antidepressant effects and neurobiological mechanisms Its preservation of breathing reflexes and cardiovascular stability make it uniquely valuable in situations where other anesthetics are dangerous: emergency rooms, battlefield medicine, resource-limited settings, and procedures on patients who cannot tolerate drops in blood pressure.
It is also widely used in veterinary medicine, for the same reasons. Ketamine works safely across a wide range of species, and its margin between effective and lethal doses is unusually large compared to many anesthetics. At sub-anesthetic doses, it serves as a powerful painkiller for acute and chronic pain, and it has been studied for conditions ranging from complex regional pain syndrome to severe burns.
Risks of Recreational and Long-Term Use
While medical ketamine under supervision has a strong safety record, recreational use carries real and sometimes serious risks. Long-term frequent use is associated with psychological dependence and tolerance, meaning users need escalating doses to achieve the same effects.15PubMed Central. The epidemiology and patterns of acute and chronic toxicity associated with recreational ketamine use
One of the most distinctive harms associated with heavy ketamine use is bladder damage. Ketamine metabolites can inflame and scar the bladder lining, leading to a condition sometimes called ketamine-induced cystitis. Symptoms include severe urinary frequency, pain, and in advanced cases, a dramatically shrunken bladder that may require surgical intervention.16PubMed Central. Pathophysiology, clinical presentation, and management of ketamine-induced cystitis This is not a rare curiosity among heavy users; urological problems are among the most commonly reported chronic effects in recreational ketamine populations.
Cognitive effects are also a concern. Studies comparing long-term recreational ketamine users to healthy controls have found impairments in verbal and visual memory, executive function, verbal fluency, and processing speed.17PubMed. Cognitive impairment in chronic ketamine abusers Neuroimaging research tells a consistent story: chronic users show lower gray matter volume, reduced white matter integrity, and diminished connectivity between the thalamus and cortex as well as between cortical regions.18PubMed Central. Brain Changes Associated With Long-Term Ketamine Abuse, A Systematic Review These structural changes may underlie the cognitive difficulties that heavy users report.
It is worth noting that the doses, frequencies, and durations involved in recreational abuse are vastly different from what happens in a clinical setting. Someone receiving a low-dose ketamine infusion for depression once every few weeks is in a very different risk category from someone using gram-level amounts recreationally multiple times per week. The bladder and brain effects described above emerge primarily from heavy, chronic, unsupervised use.
Scheduling and Access Debates
Ketamine’s unusual pharmacological profile has created an equally unusual regulatory situation. In the United States, it is classified as a Schedule III controlled substance, meaning it is recognized as having medical utility but also abuse potential. This puts it in a less restrictive category than drugs like heroin or LSD (Schedule I) or cocaine (Schedule II), and it remains one of the most widely used anesthetics globally. The World Health Organization has repeatedly placed ketamine on its Model List of Essential Medicines.
Internationally, there have been recurring debates about tightening controls on ketamine in response to growing recreational use. However, stricter scheduling carries a real tradeoff: in low- and middle-income countries, ketamine is often the only safe anesthetic available, particularly in rural settings where electricity and monitoring equipment for more complex anesthetics may be unreliable.19PubMed Central. Scheduling medicines as controlled substances: addressing normative and democratic gaps through human rights-based analysis Proponents of stricter controls point to rising rates of recreational use and associated harms; opponents argue that limiting access to an essential medicine would create serious public-health consequences in precisely the places where alternatives are least available. This tension has kept ketamine’s international scheduling status largely unchanged despite periodic pressure to reclassify it.
How Ketamine Compares to Other Dissociatives
Ketamine belongs to a broader family of dissociative substances that share NMDA receptor antagonism as a common thread. Phencyclidine (PCP), the drug from which ketamine was originally derived as a safer alternative, acts on the same primary receptor but with a much longer duration of action and a far higher incidence of prolonged agitation and psychotic episodes. Nitrous oxide (laughing gas) and dextromethorphan (found in cough suppressants) also have dissociative properties through NMDA-related mechanisms, though their overall pharmacological profiles differ substantially.
What sets ketamine apart from its dissociative relatives is its clinical safety margin and its breadth of legitimate medical use. Anesthetics that preserve airway reflexes and cardiovascular function while providing effective unconsciousness are rare, and no other dissociative has been developed into an approved psychiatric treatment. The fact that ketamine produces rapid synaptic remodeling and antidepressant effects through a mechanism shared by no existing antidepressant class is what has driven much of the research interest over the past two decades.20PubMed Central. Ketamine and Serotonergic Psychedelics: Common Mechanisms Underlying the Effects of Rapid-Acting Antidepressants
For people trying to make sense of ketamine using the “upper, downer, hallucinogen” framework that gets taught in health classes, the honest answer is that it borrows from all three without belonging to any one. It raises blood pressure and heart rate like a stimulant. It produces unconsciousness and sedation like a depressant. It triggers perceptual distortions and hallucinations. And it does something none of those categories capture: it disconnects the mind from the body in a way that has turned out to be both therapeutically useful and, when misused, genuinely damaging.